Alexion Pharmaceuticals, Inc. operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Alexion Pharmaceuticals with three other
companies in this sector in UNITED STATES :
sales of $6.68 billion
of which 53%
Vertex Pharmaceuticals Inc
of which 62%
was TRIKAFTA), and
Perrigo Company PLC
of which 53%
During the first
quarter of 2021, sales at Alexion Pharmaceuticals totalled
an increase of 13.3%
from the $1.44 billion in sales at the company during the first quarter of 2020.
During the previous 33 quarters, sales at Alexion Pharmaceuticals have increased compared with the same quarter in the previous year.
There appears to be at least some degree of seasonality in the sales at Alexion Pharmaceuticals: during 8 of the previous 9
years, sales were highest during the fourth quarter.
The exception to this was during 2017, when the
second quarter was the best quarter, accounting for
26% of sales (during that same year, the
fourth quarter accounted for 26% of sales).
During the year ended December of 2020, sales at
Alexion Pharmaceuticals were $6.07 billion.
increase of 22.5%
versus 2019, when the company's sales were $4.95 billion.
This was the fifth consecutive year of sales increases at Alexion Pharmaceuticals
(and since 2015, sales have increased a total of 133%).
Sales of Ultomiris saw an increase
that was more than double the company's growth rate: sales were up
217.7% in 2020, from
$338.90 million to $1.08 billion.